{"id":"phenamine","rwe":[{"pmid":"30000366","year":"2006","title":"Amphetamine.","finding":"","journal":"","studyType":"Clinical Study"},{"pmid":"37659801","year":"2023","title":"Chitosan/tannic acid phenamine networks-hollow mesoporous silica capsules with reversible pH response: Controlled-releasing amino acid derivatives as \"green\" corrosion inhibitor.","finding":"","journal":"Carbohydrate polymers","studyType":"Clinical Study"},{"pmid":"35504023","year":"2022","title":"Two Multiresponsive Luminescent Zn-MOFs for the Detection of Different Chemicals in Simulated Urine and Antibiotics/Cations/Anions in Aqueous Media.","finding":"","journal":"Inorganic chemistry","studyType":"Clinical Study"},{"pmid":"19621270","year":"2009","title":"Features of central neurotransmission in animals in conditions of dietary magnesium deficiency and after its correction.","finding":"","journal":"Neuroscience and behavioral physiology","studyType":"Clinical Study"},{"pmid":"19526131","year":"2009","title":"Antihypoxants, thiasolo[5,4-b]indole derivatives, increase exercise performance in rats and mice.","finding":"","journal":"Bulletin of experimental biology and medicine","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"phenocoll","offLabel":[],"synonyms":["phenocoll","phenamine","phenokoll"],"timeline":[],"approvals":[],"brandName":"Phenocoll","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Unfortunately, the exact mechanism of action of phenocoll is not well understood, and more research is needed to determine how it produces its effects. In general, small molecule drugs like phenocoll work by binding to a specific protein or receptor in the body, which can alter the way that cells function and communicate with each other. This can lead to changes in various physiological processes, such as the regulation of chemical signals or the contraction of muscles.","oneSentence":"Phenocoll works by interacting with a specific target in the body to produce a therapeutic effect.","technicalDetail":"Phenocoll's mechanism of action is likely to involve the modulation of a specific molecular target, potentially through the inhibition or activation of a particular enzyme or receptor. Further research is needed to determine the precise molecular details of its mechanism of action."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3437","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=phenamine","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=phenamine","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:17:56.481887","biosimilars":[],"competitors":[],"genericName":"phenamine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07479771","phase":"NA","title":"tTIS Targeted of the Striatum as an Intervention for MUD Patients","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Mental Health Center","startDate":"2026-03-26","conditions":["Amphetamine Use Disorders"],"enrollment":60,"completionDate":"2026-06-30"},{"nctId":"NCT06853665","phase":"PHASE4","title":"The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine","status":"RECRUITING","sponsor":"Gagan Joshi","startDate":"2026-02-01","conditions":["Attention Deficit Hyperactivity Disorder (ADHD)","Autism","Autism Spectrum Disorder"],"enrollment":196,"completionDate":"2030-02-01"},{"nctId":"NCT07314333","phase":"PHASE1","title":"A Trial to Assess How Centanafadine Interacts With Stimulants in the Body","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2026-02-05","conditions":["ADHD"],"enrollment":42,"completionDate":"2026-04-03"},{"nctId":"NCT05854667","phase":"PHASE2","title":"Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2023-12-05","conditions":["Methamphetamine Abuse","Methamphetamine-dependence","Addiction, Substance","Addiction"],"enrollment":440,"completionDate":"2028-04"},{"nctId":"NCT04599504","phase":"PHASE2,PHASE3","title":"Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2022-01-02","conditions":["Loss-of-control Eating","Obesity/Overweight"],"enrollment":60,"completionDate":"2027-05"},{"nctId":"NCT05380440","phase":"NA","title":"Preventing Parental Opioid and/or Methamphetamine Addiction Within DHS-Involved Families: PRE-FAIR","status":"COMPLETED","sponsor":"Chestnut Health Systems","startDate":"2021-06-09","conditions":["Opioid-Related Disorders","Stimulant-Related Disorder","Child Neglect","Mental Health Impairment"],"enrollment":241,"completionDate":"2025-06-02"},{"nctId":"NCT05416125","phase":"EARLY_PHASE1","title":"Vyvanse in Children Aged 6 to 12 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Minnesota","startDate":"2023-12-20","conditions":["Obesity, Childhood"],"enrollment":44,"completionDate":"2027-07-31"},{"nctId":"NCT04414930","phase":"PHASE2","title":"Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2020-11-09","conditions":["Schizophrenia","Schizoaffective Disorder"],"enrollment":68,"completionDate":"2024-12-30"},{"nctId":"NCT03926052","phase":"PHASE3","title":"Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment","status":"COMPLETED","sponsor":"Yale University","startDate":"2019-08-07","conditions":["Binge-Eating Disorder","Obesity"],"enrollment":61,"completionDate":"2024-11-18"},{"nctId":"NCT06165198","phase":"NA","title":"Individualized Neuromodulation for the Core Clinical Features of Drug Addiction","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2023-09-25","conditions":["Amphetamine Use Disorders"],"enrollment":9,"completionDate":"2024-09-25"},{"nctId":"NCT05916339","phase":"PHASE4","title":"AWARE: Management of ADHD in Autism Spectrum Disorder","status":"RECRUITING","sponsor":"Daniel Coury","startDate":"2023-10-01","conditions":["ADHD","Autism Spectrum Disorder"],"enrollment":500,"completionDate":"2027-12-30"},{"nctId":"NCT07169162","phase":"PHASE4","title":"ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder","status":"WITHDRAWN","sponsor":"Aytu BioPharma, Inc.","startDate":"2019-05","conditions":["Attention Deficit Hyperactivity Disorder"],"enrollment":0,"completionDate":"2025-09-05"},{"nctId":"NCT06847399","phase":"PHASE2","title":"Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-09-17","conditions":["Obesity and Overweight","Binge Eating Disorder"],"enrollment":105,"completionDate":"2027-12-01"},{"nctId":"NCT01071044","phase":"PHASE4","title":"Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome","status":"COMPLETED","sponsor":"Rochester Center for Behavioral Medicine","startDate":"2009-11","conditions":["Chronic Fatigue Syndrome","Cognitive Impairments"],"enrollment":26,"completionDate":"2011-03"},{"nctId":"NCT04235686","phase":"PHASE2","title":"8 Week Multi-site Study of MYDAYIS® for Bipolar Depression","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2020-07-17","conditions":["Bipolar Depression"],"enrollment":74,"completionDate":"2025-07-25"},{"nctId":"NCT06681376","phase":"NA","title":"Enhancing the Emergency Department Experience for Older Adults: Study Protocol for the Implementation of a Comfort Menu and Cart","status":"NOT_YET_RECRUITING","sponsor":"Hospital Sirio-Libanes","startDate":"2026-04","conditions":["Emergency Department Patient","Comfort"],"enrollment":264,"completionDate":"2027-06"},{"nctId":"NCT03511976","phase":"PHASE4","title":"Adaptive Response to Intervention (RTI) for Students With ADHD","status":"WITHDRAWN","sponsor":"Florida International University","startDate":"2018-05-14","conditions":["Attention Deficit Disorder With Hyperactivity"],"enrollment":0,"completionDate":"2023-10-21"},{"nctId":"NCT07100314","phase":"","title":"Preoperative Toxicological Screening on Perioperative Anesthetic Management","status":"COMPLETED","sponsor":"General Committee of Teaching Hospitals and Institutes, Egypt","startDate":"2023-12-01","conditions":["Toxicology","Bariatric Surgery Analgesia","Bariatric Surgery","Substance Use"],"enrollment":1260,"completionDate":"2024-06-01"},{"nctId":"NCT07098585","phase":"PHASE1","title":"To Compare and Evaluate the Oral Bioavailability of Lisdexamfetamine 70 mg Capsule With That of Elvanse® 70 mg Capsules, Hard Lisdexamfetamine Dimesylate in Healthy, Adult, Human Subjects Under Fasting Conditions.","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2025-05-26","conditions":["Attention Deficit/Hyperactivity Disorder (ADHD)"],"enrollment":48,"completionDate":"2025-07-17"},{"nctId":"NCT03460353","phase":"","title":"Bariatric Surgery and Pharmacokinetics of Dexamphetamine","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2016-11-02","conditions":["Obesity, Morbid"],"enrollment":12,"completionDate":"2018-06-04"},{"nctId":"NCT04132557","phase":"","title":"A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-10-09","conditions":["Attention Deficit Disorder With Hyperactivity"],"enrollment":430000,"completionDate":"2019-10-25"},{"nctId":"NCT03497169","phase":"","title":"Bariatric Surgery and Pharmacokinetics of Lisdexamphetamine","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2016-11-02","conditions":["Obesity, Morbid"],"enrollment":12,"completionDate":"2020-09-28"},{"nctId":"NCT05011760","phase":"EARLY_PHASE1","title":"[C-11]NPA PET-amphetamine in Cocaine Use Disorders","status":"RECRUITING","sponsor":"Rajesh Narendran","startDate":"2021-01-31","conditions":["Cocaine Use Disorder"],"enrollment":30,"completionDate":"2028-09-01"},{"nctId":"NCT06960265","phase":"NA","title":"Effects of Repetitive Transcranial Magnetic Stimulations in Patients With Amphetamine Use Disorders","status":"NOT_YET_RECRUITING","sponsor":"TsaoTun Psychiatric Center, Department of Health, Taiwan","startDate":"2025-05-15","conditions":["Amphetamine Use Disorders","Amphetamine Use Disorder","Amphetamine Dependence","Amphetamine Abuse","NIRS","rTMS","rTMS Stimulation"],"enrollment":20,"completionDate":"2025-12-31"},{"nctId":"NCT01342445","phase":"PHASE4","title":"Effects of LDX on Functioning of College Students With ADHD","status":"COMPLETED","sponsor":"University of Rhode Island","startDate":"2009-09","conditions":["Attention-deficit/Hyperactivity Disorder"],"enrollment":50,"completionDate":"2010-12"},{"nctId":"NCT05790239","phase":"PHASE2","title":"MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder","status":"RECRUITING","sponsor":"Stephen Robert Marder","startDate":"2025-03-01","conditions":["Post Traumatic Stress Disorder"],"enrollment":40,"completionDate":"2026-03"},{"nctId":"NCT03420339","phase":"PHASE4","title":"Stimulant Effects on Disruptive Behavior","status":"RECRUITING","sponsor":"Matthew J O'Brien, PhD, BCBA-D","startDate":"2018-10-01","conditions":["Attention Deficit Hyperactivity Disorder","Problem Behavior"],"enrollment":10,"completionDate":"2027-08-01"},{"nctId":"NCT01140880","phase":"PHASE2","title":"Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men","status":"COMPLETED","sponsor":"Friends Research Institute, Inc.","startDate":"2010-05","conditions":["HIV Seroconversion","Stimulant Abuse"],"enrollment":170,"completionDate":"2013-03"},{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":["Coronavirus Infection (COVID-19)","Pulmonary Arterial Hypertension","Urinary Tract Infections in Children","Hypertension","Pain","Hyperphosphatemia","Primary Hyperaldosteronism","Edema","Hypokalemia","Heart Failure","Hemophilia","Menorrhagia","Insomnia","Pneumonia","Skin Infection","Arrythmia","Asthma in Children","Bronchopulmonary Dysplasia","Adrenal Insufficiency","Fibrinolysis; Hemorrhage","Attention Deficit Hyperactivity Disorder","Multisystem Inflammatory Syndrome in Children (MIS-C)","Kawasaki Disease","Coagulation Disorder","Down Syndrome"],"enrollment":5000,"completionDate":"2027-09"},{"nctId":"NCT05621174","phase":"NA","title":"The Difference in the Mechanism of Action Between Two Brands of Dexamfetamine in Adults With ADHD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2023-04-14","conditions":["Attention Deficit Disorder With Hyperactivity"],"enrollment":1,"completionDate":"2025-12-31"},{"nctId":"NCT05066009","phase":"NA","title":"Sleep/Wake State Assessment with Non-invasive Earbuds","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-10-13","conditions":["Hypersomnolence"],"enrollment":8,"completionDate":"2023-10-27"},{"nctId":"NCT02515955","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Participants","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2015-08","conditions":["Healthy"],"enrollment":76,"completionDate":"2016-03"},{"nctId":"NCT04908410","phase":"","title":"The Norwegian Addiction, Pain and Trauma Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Akershus","startDate":"2021-03-23","conditions":["Chronic Pain","Post-traumatic Stress Disorder","Substance Use Disorders"],"enrollment":1650,"completionDate":"2030-12-31"},{"nctId":"NCT05650775","phase":"PHASE1","title":"Biomarkers of ADHD Treatment Response","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2023-02-17","conditions":["ADHD"],"enrollment":16,"completionDate":"2024-03-30"},{"nctId":"NCT04240756","phase":"PHASE3","title":"Treating Parents with ADHD and Their Young Children Via Telehealth: a Hybrid Type I Effectiveness-Implementation Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Maryland, College Park","startDate":"2020-08-06","conditions":["ADHD","Parenting"],"enrollment":240,"completionDate":"2025-07-31"},{"nctId":"NCT05957055","phase":"PHASE2","title":"Lisdexamphetamine Vs Methylphenidate for Pediatric Patients with ADHD and Type 1 Diabetes","status":"RECRUITING","sponsor":"Medical University of Lodz","startDate":"2024-02-05","conditions":["Attention Deficit Disorder with Hyperactivity","Diabetes Mellitus, Type 1"],"enrollment":150,"completionDate":"2027-12-01"},{"nctId":"NCT06701487","phase":"","title":"Role of Pavlovian Mechanisms for Control Over Substance Use","status":"RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2024-08-05","conditions":["Alcohol Use Disorder (AUD)","Alcoholism","Substance Use Disorders","Cannabis Use Disorder","Methamphetamine-dependence","Amphetamine Use Disorder","Cocaine Use Disorder"],"enrollment":200,"completionDate":"2027-06-30"},{"nctId":"NCT06248229","phase":"PHASE4","title":"A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD).","status":"RECRUITING","sponsor":"Rochester Center for Behavioral Medicine","startDate":"2024-09-01","conditions":["Fatigue","Attention Deficit Hyperactivity Disorder","Attention Deficit Disorder"],"enrollment":50,"completionDate":"2026-12-01"},{"nctId":"NCT02676739","phase":"PHASE2,PHASE3","title":"Adderall XR and Cognitive Impairment in MS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sarah Morrow","startDate":"2016-05-20","conditions":["Multiple Sclerosis"],"enrollment":180,"completionDate":"2024-12"},{"nctId":"NCT03924193","phase":"PHASE3","title":"Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment","status":"COMPLETED","sponsor":"Yale University","startDate":"2019-03-25","conditions":["Binge-Eating Disorder","Obesity"],"enrollment":141,"completionDate":"2023-09-13"},{"nctId":"NCT03659929","phase":"PHASE3","title":"Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate","status":"COMPLETED","sponsor":"Arbor Pharmaceuticals, Inc.","startDate":"2018-09-18","conditions":["Attention Deficit Hyperactivity Disorder"],"enrollment":320,"completionDate":"2019-04-12"},{"nctId":"NCT04170738","phase":"PHASE4","title":"Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder","status":"COMPLETED","sponsor":"Jeffrey Newcorn","startDate":"2019-11-05","conditions":["Attention Deficit Disorder With Hyperactivity","Conduct Disorder","Substance Abuse"],"enrollment":33,"completionDate":"2023-08-08"},{"nctId":"NCT02773212","phase":"PHASE2","title":"Targeting Anhedonia in Cocaine Use Disorder","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2017-02-01","conditions":["Cocaine-Related Disorders","Anhedonia"],"enrollment":57,"completionDate":"2022-04-04"},{"nctId":"NCT05597722","phase":"PHASE4","title":"Addressing Cognitive Fog in Long-COVID-19 Patients","status":"TERMINATED","sponsor":"Eva Szigethy","startDate":"2023-04-04","conditions":["Cognitive Impairment","Long COVID"],"enrollment":7,"completionDate":"2023-05-18"},{"nctId":"NCT04823364","phase":"NA","title":"Evaluation of Brain Neurotransmitter Levels in Adults With ADHD, Before and After Stimulant Treatment","status":"TERMINATED","sponsor":"Weizmann Institute of Science","startDate":"2024-07-11","conditions":["Attention Deficit Disorder With Hyperactivity"],"enrollment":60,"completionDate":"2024-07-11"},{"nctId":"NCT06457243","phase":"NA","title":"Closed-loop cTBS for the Core Clinical Features of Methamphetamine Use Disorder","status":"RECRUITING","sponsor":"Shanghai Mental Health Center","startDate":"2024-08","conditions":["Amphetamine Use Disorders"],"enrollment":30,"completionDate":"2025-08"},{"nctId":"NCT03772314","phase":"PHASE2","title":"Modafinil Versus Amphetamines for the Treatment of Narcolepsy Type 2 and Idiopathic Hypersomnia","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-04-15","conditions":["Idiopathic Hypersomnia","Narcolepsy Without Cataplexy"],"enrollment":44,"completionDate":"2023-05-04"},{"nctId":"NCT05551689","phase":"NA","title":"FOCUS ADHD Mobile Health App for Adult ADHD Patients","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2021-05-21","conditions":["ADHD"],"enrollment":73,"completionDate":"2023-03-30"},{"nctId":"NCT05515757","phase":"NA","title":"Hospital-Based Contingency Management","status":"ENROLLING_BY_INVITATION","sponsor":"Oregon Health and Science University","startDate":"2022-08-22","conditions":["Amphetamine-Related Disorders"],"enrollment":90,"completionDate":"2024-12"},{"nctId":"NCT03103750","phase":"PHASE1","title":"Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-08-15","conditions":["ADHD"],"enrollment":24,"completionDate":"2023-01-17"},{"nctId":"NCT03337646","phase":"PHASE4","title":"Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism","status":"COMPLETED","sponsor":"JPM van Stralen Medicine Professional","startDate":"2018-09-26","conditions":["Attention Deficit Hyperactivity Disorder","Autism Spectrum Disorder"],"enrollment":48,"completionDate":"2023-03-31"},{"nctId":"NCT01711021","phase":"PHASE2","title":"Study to Evaluate Safety & Efficacy of d-Amphetamine Transdermal System vs Placebo in Children & Adolescents With ADHD","status":"COMPLETED","sponsor":"Noven Pharmaceuticals, Inc.","startDate":"2012-10","conditions":["Attention Deficit Hyperactivity Disorder"],"enrollment":110,"completionDate":"2013-03"},{"nctId":"NCT00439049","phase":"","title":"Substance Abuse Pre-Treatment Screening Study","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2005-10","conditions":["Cocaine Abuse","Cocaine Dependence","Opiate Dependence","Alcohol Dependence","Substance Abuse"],"enrollment":7500,"completionDate":"2026-06"},{"nctId":"NCT03187353","phase":"PHASE4","title":"IMProving Executive Function Study","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2017-09-22","conditions":["Cognitive Impairment","RRSO"],"enrollment":69,"completionDate":"2022-04-30"},{"nctId":"NCT03834766","phase":"PHASE3","title":"Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD","status":"COMPLETED","sponsor":"Tris Pharma, Inc.","startDate":"2019-02-06","conditions":["ADHD"],"enrollment":130,"completionDate":"2019-10-19"},{"nctId":"NCT02008292","phase":"NA","title":"Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors","status":"COMPLETED","sponsor":"Yale University","startDate":"2013-09","conditions":["Smoking","Schizophrenia"],"enrollment":80,"completionDate":"2021-12"},{"nctId":"NCT02136147","phase":"","title":"ADHD Medication and Predictors of Treatment Outcome","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2015-06","conditions":["Attention Deficit Disorder With Hyperactivity (ADHD)"],"enrollment":632,"completionDate":"2022-06"},{"nctId":"NCT02478788","phase":"PHASE4","title":"Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2015-11","conditions":["Attention Deficit Hyperactivity Disorder"],"enrollment":153,"completionDate":"2022-12"},{"nctId":"NCT03922646","phase":"NA","title":"Neurocognitive Empowerment for Addiction Treatment (NEAT) in Opioid Use Disorder and Amphetamine Use Disorder","status":"COMPLETED","sponsor":"Laureate Institute for Brain Research, Inc.","startDate":"2019-03-06","conditions":["Opioid-use Disorder","Amphetamine Use Disorders"],"enrollment":104,"completionDate":"2023-05-12"},{"nctId":"NCT02058693","phase":"PHASE4","title":"Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2010-12","conditions":["Major Depressive Disorder"],"enrollment":41,"completionDate":"2014-12"},{"nctId":"NCT01217970","phase":"PHASE1","title":"Safety Interaction Trial Ibudilast and Methamphetamine","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2011-01","conditions":["Methamphetamine-dependence","Substance Abuse"],"enrollment":11,"completionDate":"2013-03"},{"nctId":"NCT04946461","phase":"","title":"The Day-time Response Variation of (Lis)Dexamphetamine","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2021-07-01","conditions":["Adhd"],"enrollment":16,"completionDate":"2022-06-16"},{"nctId":"NCT04993300","phase":"NA","title":"Repetitive Transcranial Magnetic Stimulation in Amphetamine Addiction","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2022-02-17","conditions":["Craving","Depression, Anxiety","Amphetamine Addiction"],"enrollment":5,"completionDate":"2022-08-04"},{"nctId":"NCT02348385","phase":"","title":"Imaging Extrastriatal Dopamine Release in Tobacco Smokers and Nonsmokers","status":"COMPLETED","sponsor":"Yale University","startDate":"2012-12","conditions":["Nicotine Dependence"],"enrollment":49,"completionDate":"2017-12"},{"nctId":"NCT03810703","phase":"PHASE1","title":"Differential Responses to Drugs and Sweet Tastes","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2017-02-09","conditions":["Bipolar II Disorder"],"enrollment":93,"completionDate":"2018-08-09"},{"nctId":"NCT03198962","phase":"","title":"Use of Amphetamine-type Stimulants & Its Relationship With HIV Incidence and Antiretroviral Adherence Among MSM and TG","status":"COMPLETED","sponsor":"Thai Red Cross AIDS Research Centre","startDate":"2016-11-15","conditions":["HIV Infections"],"enrollment":510,"completionDate":"2023-02-16"},{"nctId":"NCT01074294","phase":"PHASE2","title":"Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-03-16","conditions":["Attention Deficit Hyperactivity Disorder"],"enrollment":740,"completionDate":"2011-06-20"},{"nctId":"NCT02259517","phase":"NA","title":"An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2014-09","conditions":["Attention Deficit Hyperactivity Disorder"],"enrollment":38,"completionDate":"2021-11-06"},{"nctId":"NCT04577417","phase":"","title":"Stimulant Medication Effects on Auditory Sensitivity in Teens With ADHD","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2020-09-13","conditions":["Attention Deficit Hyperactivity Disorder","Attention Deficit Disorder","Attention Deficit Disorder With Hyperactivity"],"enrollment":70,"completionDate":"2022-06-15"},{"nctId":"NCT04968522","phase":"PHASE4","title":"FASST - Fetal Alcohol Spectrum Stimulant Trial","status":"UNKNOWN","sponsor":"Monash Medical Centre","startDate":"2022-02-14","conditions":["Fetal Alcohol Spectrum Disorders"],"enrollment":20,"completionDate":"2023-07"},{"nctId":"NCT05611385","phase":"","title":"Amphetamine Induced Adult Respiratory Distress Syndrome","status":"COMPLETED","sponsor":"Arrowhead Regional Medical Center","startDate":"2019-01-01","conditions":["Burns","Acute Lung Injury","Acute Respiratory Distress Syndrome","Methamphetamine Abuse"],"enrollment":49,"completionDate":"2020-01-01"},{"nctId":"NCT03153488","phase":"NA","title":"Attention Deficit Hyperactivity Disorder (ADHD) Prediction of Treatment Response","status":"UNKNOWN","sponsor":"Massachusetts General Hospital","startDate":"2018-07-01","conditions":["Attention Deficit Hyperactivity Disorder"],"enrollment":60,"completionDate":"2023-12-01"},{"nctId":"NCT01615887","phase":"PHASE2","title":"Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple Sclerosis","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2009-11","conditions":["Multiple Sclerosis"],"enrollment":63,"completionDate":"2011-08"},{"nctId":"NCT05535101","phase":"NA","title":"Non-invasive Brain Stimulation in Patients With Methamphetamine Use Disorder","status":"UNKNOWN","sponsor":"National Taiwan University Hospital Hsin-Chu Branch","startDate":"2022-09-01","conditions":["Craving","Depression, Anxiety","Amphetamine Addiction"],"enrollment":60,"completionDate":"2023-12-31"},{"nctId":"NCT03333668","phase":"NA","title":"Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents","status":"UNKNOWN","sponsor":"King's College London","startDate":"2018-10-01","conditions":["ADHD"],"enrollment":20,"completionDate":"2025-03-31"},{"nctId":"NCT01415440","phase":"NA","title":"Imaging the Effects of Stimulant Medication on Emotional Lability in Patients With ADHD","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2011-08","conditions":["Attention Deficit Hyperactivity Disorder"],"enrollment":117,"completionDate":"2018-06"},{"nctId":"NCT02630069","phase":"PHASE2","title":"CDP-choline Treatment in ATS Users","status":"UNKNOWN","sponsor":"Ewha Womans University Mokdong Hospital","startDate":"2015-03","conditions":["Substance Use Disorders"],"enrollment":160,"completionDate":"2022-12"},{"nctId":"NCT05312359","phase":"NA","title":"Brain Mechanism and Intervention of Executive-control Dysfunction Among Substance Dependents","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2022-06-01","conditions":["Substance Dependence","Executive Function Disorder","Transcranial Alternating Current Stimulation"],"enrollment":210,"completionDate":"2025-12-31"},{"nctId":"NCT03242772","phase":"PHASE2","title":"Impact of Combined Medication and Behavioral Treatment for ASD & ADHD","status":"TERMINATED","sponsor":"Duke University","startDate":"2018-12-14","conditions":["Autism Spectrum Disorder","Attention Deficit Hyperactivity Disorder"],"enrollment":18,"completionDate":"2021-04-19"},{"nctId":"NCT00500071","phase":"PHASE4","title":"Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD","status":"COMPLETED","sponsor":"Shire","startDate":"2007-06-28","conditions":["Attention Deficit Hyperactivity Disorder (ADHD)"],"enrollment":318,"completionDate":"2008-01-02"},{"nctId":"NCT04027361","phase":"PHASE2","title":"Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Tris Pharma, Inc.","startDate":"2019-10-01","conditions":["ADHD"],"enrollment":41,"completionDate":"2021-10-15"},{"nctId":"NCT01986075","phase":"PHASE1,PHASE2","title":"A Sequenced Behavioral and Medication Intervention for Cocaine Dependence","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2014-01","conditions":["Cocaine Dependence"],"enrollment":145,"completionDate":"2021-01"},{"nctId":"NCT04647903","phase":"PHASE1","title":"Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR)","status":"COMPLETED","sponsor":"Vallon Pharmaceuticals, Inc.","startDate":"2020-10-05","conditions":["ADHD","Narcolepsy"],"enrollment":55,"completionDate":"2021-12-17"},{"nctId":"NCT02635035","phase":"PHASE2","title":"Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2015-11","conditions":["Attention Deficit Disorder","Attention Deficit Hyperactivity Disorder"],"enrollment":38,"completionDate":"2019-01-09"},{"nctId":"NCT03736317","phase":"NA","title":"Transcranial Magnetic Stimulation for Treatment of Methamphetamine Use Disorder","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2019-09-01","conditions":["Amphetamine Use Disorders"],"enrollment":144,"completionDate":"2021-09-01"},{"nctId":"NCT04152629","phase":"PHASE4","title":"Real World Evidence of the Efficacy and Safety of FOQUEST","status":"COMPLETED","sponsor":"Purdue Pharma, Canada","startDate":"2019-09-19","conditions":["Attention Deficit-Hyperactivity Disorder"],"enrollment":257,"completionDate":"2021-07-09"},{"nctId":"NCT00152035","phase":"PHASE3","title":"Safety of SPD465 in Treating Adults With ADHD.","status":"COMPLETED","sponsor":"Shire","startDate":"2005-03-10","conditions":["Attention Deficit Disorder With Hyperactivity"],"enrollment":505,"completionDate":"2006-11-07"},{"nctId":"NCT02634684","phase":"PHASE2","title":"Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2014-07-01","conditions":["Schizophrenia"],"enrollment":82,"completionDate":"2020-08"},{"nctId":"NCT04727476","phase":"","title":"The Use of Lisdexamfetamine for Children Aged 7-13 With Attention Deficit Disorders","status":"UNKNOWN","sponsor":"Aarhus University Hospital","startDate":"2021-01-19","conditions":["Attention Deficit Disorder","Attention Deficit Hyperactivity Disorder","Hyperkinetic Disorder"],"enrollment":413,"completionDate":"2022-05-01"},{"nctId":"NCT01232361","phase":"","title":"IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-10-08","conditions":["ADHD","HIV"],"enrollment":127,"completionDate":"2016-07"},{"nctId":"NCT02884544","phase":"PHASE2","title":"A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD","status":"COMPLETED","sponsor":"Ironshore Pharmaceuticals and Development, Inc","startDate":"2016-08","conditions":["Attention-Deficit Hyperactivity Disorder (ADHD)"],"enrollment":22,"completionDate":"2016-12-27"},{"nctId":"NCT01718509","phase":"PHASE3","title":"SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2012-11-26","conditions":["Binge Eating Disorder"],"enrollment":390,"completionDate":"2013-09-20"},{"nctId":"NCT00152022","phase":"PHASE3","title":"Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD.","status":"COMPLETED","sponsor":"Shire","startDate":"2005-04-25","conditions":["Attention Deficit Disorder With Hyperactivity"],"enrollment":412,"completionDate":"2005-11-04"},{"nctId":"NCT00150579","phase":"PHASE3","title":"Efficacy and Safety of SPD465 in Adults With ADHD","status":"COMPLETED","sponsor":"Shire","startDate":"2005-01-27","conditions":["Attention Deficit Disorder With Hyperactivity"],"enrollment":240,"completionDate":"2005-06-14"},{"nctId":"NCT00202605","phase":"PHASE2","title":"Safety and Efficacy of SPD465 in Adults With ADHD","status":"COMPLETED","sponsor":"Shire","startDate":"2005-09-29","conditions":["Attention Deficit Disorder With Hyperactivity"],"enrollment":72,"completionDate":"2006-01-06"},{"nctId":"NCT03446885","phase":"PHASE4","title":"Efficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With ADHD","status":"COMPLETED","sponsor":"Gregory Fabiano","startDate":"2018-04-01","conditions":["Attention Deficit Disorder With Hyperactivity"],"enrollment":22,"completionDate":"2019-08-30"},{"nctId":"NCT01760993","phase":"PHASE3","title":"Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia","status":"TERMINATED","sponsor":"Shire","startDate":"2013-02-01","conditions":["Schizophrenia"],"enrollment":2,"completionDate":"2013-04-01"},{"nctId":"NCT01738698","phase":"PHASE3","title":"Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia","status":"TERMINATED","sponsor":"Shire","startDate":"2012-11-01","conditions":["Schizophrenia"],"enrollment":4,"completionDate":"2013-04-01"},{"nctId":"NCT01760889","phase":"PHASE3","title":"SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia","status":"TERMINATED","sponsor":"Shire","startDate":"2013-02-01","conditions":["Schizophrenia"],"enrollment":1,"completionDate":"2013-04-01"},{"nctId":"NCT00877487","phase":"PHASE4","title":"Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2009-04-30","conditions":["Attention-Deficit/Hyperactivity Disorder"],"enrollment":123,"completionDate":"2010-07-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"MMSL":"31375","NDDF":"001790","UNII":"WY440H625W","CHEBI":"CHEBI:134848","VANDF":"4019611","RXNORM":"725","UMLSCUI":"C0002658","PUBCHEM_CID":"66901","SNOMEDCT_US":"22672005"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":188,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2006","pmid":"30000366","title":"Amphetamine.","journal":""},{"date":"2023 Nov 15","pmid":"37659801","title":"Chitosan/tannic acid phenamine networks-hollow mesoporous silica capsules with reversible pH response: Controlled-releasing amino acid derivatives as \"green\" corrosion inhibitor.","journal":"Carbohydrate polymers"},{"date":"2022 May 16","pmid":"35504023","title":"Two Multiresponsive Luminescent Zn-MOFs for the Detection of Different Chemicals in Simulated Urine and Antibiotics/Cations/Anions in Aqueous Media.","journal":"Inorganic chemistry"},{"date":"2009 Sep","pmid":"19621270","title":"Features of central neurotransmission in animals in conditions of dietary magnesium deficiency and after its correction.","journal":"Neuroscience and behavioral physiology"},{"date":"2009 Jan","pmid":"19526131","title":"Antihypoxants, thiasolo[5,4-b]indole derivatives, increase exercise performance in rats and mice.","journal":"Bulletin of experimental biology and medicine"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Phenocoll (phenamine) is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not known whether it is FDA approved or off-patent. There is limited information available on its approved indications, half-life, and bioavailability. Further research is needed to understand its mechanism of action and key safety considerations. As a result, it is difficult to provide a comprehensive summary of this drug.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}